A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00097578 |
Recruitment Status
:
Completed
First Posted
: November 25, 2004
Last Update Posted
: March 28, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Colorectal Cancer |
Study Type : | Observational |
Actual Enrollment : | 1953 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Adenocarcinoma |
Study Start Date : | March 2004 |
Actual Primary Completion Date : | July 2008 |
Actual Study Completion Date : | July 2008 |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Signed Informed Consent and Authorization document
- Metastatic, or locally advanced and unresectable, adenocarcinoma of the colon or rectum
- Receiving Avastin as a component of first-line chemotherapy
- First-line chemotherapy plus Avastin initiated <=4 months prior to enrollment in the study
Exclusion Criteria:
- Patients who have contraindications for treatment with Avastin (see the Avastin Package Insert) or who would incur excessive risks with Avastin treatment are ineligible for this study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00097578
United States, California | |
Genentech Central Contact | |
South San Francisco, California, United States, 94080 |
Study Director: | Eric Hedrick, M.D. | Genentech, Inc. |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Genentech, Inc. |
ClinicalTrials.gov Identifier: | NCT00097578 History of Changes |
Other Study ID Numbers: |
AVF2941n |
First Posted: | November 25, 2004 Key Record Dates |
Last Update Posted: | March 28, 2013 |
Last Verified: | March 2013 |
Additional relevant MeSH terms:
Colorectal Neoplasms Adenocarcinoma Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases |
Rectal Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Bevacizumab Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents |